TGFB2 antibody binds to the TGFB2 isoform (UniProt ID: P61812), one of three TGF-β isoforms (TGFB1, TGFB2, TGFB3) with distinct roles in cellular processes . Unlike pan-TGF-β antibodies, TGFB2-specific antibodies enable isoform-selective studies, critical for dissecting context-dependent signaling in development, immunity, and disease .
Clonality: Monoclonal, ensuring consistent binding specificity .
Applications: Validated for Western Blotting, Immunohistochemistry (IHC-P), and Immunofluorescence (IF) .
TGFB2 antibodies block TGFB2 binding to its receptor (TGFβ RII), inhibiting downstream Smad2/3 phosphorylation and suppressing TGF-β-mediated pathways . This inhibition disrupts processes like epithelial-mesenchymal transition (EMT), stromal activation, and immunosuppressive cell recruitment .
Cancer: Neutralizing TGFB2 antibodies reduce immunosuppressive myeloid cells and reverse TGF-β-mediated Treg expansion, enhancing antitumor immunity .
Fibrosis: TGFB2 signaling promotes extracellular matrix deposition; antibody blockade mitigates fibrotic progression .
Specificity Issues: Cross-reactivity with TGFB1/TGFB3 remains a concern, necessitating rigorous isoform validation .
Therapeutic Limitations: TGF-β’s dual role in tumor suppression (early) and promotion (late) complicates antibody dosing .
Combination Strategies: Synergy observed with cyclophosphamide suggests enhanced efficacy in metastatic settings .